TB-500 (Thymosin Beta-4) Peptide: Research Overview, Purity Data and Where to Buy

TB-500 is a synthetic peptide corresponding to a short, biologically active region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-binding protein found in most mammalian cells and extracellular fluids. Laboratory research examines its reported roles in actin regulation, cell migration, angiogenesis signaling, inflammatory modulation, and tissue-repair processes. It is distributed for research use only.

What TB-500 Is and Where It Came From

Thymosin beta-4 was first isolated from thymus tissue, which is how the beta-thymosin family got its name, but subsequent work showed it is not thymus-specific at all. Tβ4 is one of the most abundant small proteins inside many cell types, and it appears in wound fluid, blood platelets, and a range of tissues. Its principal described function is intracellular: it binds monomeric actin and helps maintain the pool of unpolymerized actin that cells draw on when they change shape, migrate, or remodel their cytoskeleton.

TB-500 and Tβ4 are related but not interchangeable terms. In the research-supply world, "TB-500" generally refers to a synthetic fragment built around the actin-binding motif of the parent protein — most commonly discussed as the LKKTETQ region and surrounding residues — while "thymosin beta-4" refers to the full-length native sequence. Some suppliers use the names loosely. That ambiguity is exactly why identity confirmation on a certificate of analysis matters more here than for many other research peptides, and it is a distinction covered in depth in our dedicated sequence and COA articles.

Why the fragment approach exists

The rationale reported in the literature is that much of the actin-binding and cell-motility activity of Tβ4 maps to a compact region of the molecule. Synthesizing a shorter peptide is more tractable at scale and produces a more chemically consistent product than recombinant expression of the full protein, though full-length Tβ4 is also produced recombinantly for research — including work expressing beta-thymosin sequences from non-mammalian organisms in yeast systems to study conserved biological activity.

Reported Mechanism of Action

The mechanistic picture that emerges across published work is less "one receptor, one pathway" and more "a small peptide that touches several regulatory systems at once." Researchers generally describe the following threads.

Actin sequestration and cytoskeletal dynamics

The best-characterized activity is binding to globular (G) actin, which influences the equilibrium between monomeric actin and filamentous (F) actin. Because cell migration, adhesion turnover, and morphological change all depend on regulated actin polymerization, alterations in this pool are the proposed upstream explanation for many downstream observations in migration and repair assays.

Angiogenesis and endothelial migration

Multiple preclinical reports describe increased endothelial cell migration and tube-formation behavior in the presence of Tβ4, with associated changes in vascular growth factor signaling. This is a recurring theme in wound-model literature, where new vessel formation is a rate-limiting step in tissue remodeling.

Inflammatory and immune modulation

Published work has examined Tβ4 in the context of macrophage phenotype, reporting shifts toward an M2-associated, resolution-phase profile in a mouse model of non-alcoholic fatty liver disease. Other reports in kidney injury models describe reduced injury markers alongside suppressed MAPK pathway signaling. These are model-system findings, and the causal chain from actin biology to immune phenotype is still being worked out.

Anti-fibrotic signaling and the Ac-SDKP question

Tβ4 can be enzymatically processed to release the tetrapeptide Ac-SDKP, which has its own literature in fibrosis and hematopoietic regulation. Review-level work has framed Tβ4 as sitting near an "anti-fibrotic switch," though authors in this area are careful to note that context, timing, and tissue type appear to determine whether the net effect in a model is pro-repair or pro-remodeling.

What the Research Literature Examines

The published body of work on Tβ4 is broad and mostly preclinical. Below is how the research areas cluster, with the appropriate hedging: the majority of findings come from rodent models, cell culture, and more recently human organoid systems. Early clinical work exists in a few areas but evidence remains preliminary.

Dermal and diabetic wound models

Wound repair is the most developed area. Investigators have examined Tβ4 in cutaneous injury models with endpoints such as closure rate, re-epithelialization, vascular density, and inflammatory cell profiles. More recent work has moved toward delivery engineering — for example, sprayable bioadhesive microcarriers loaded with exosomes derived from Tβ4-engineered adipose-derived stem cells, evaluated in a diabetic wound-healing model. The trend is instructive: much current research is less about the free peptide and more about how it is presented to tissue.

Cardiac, vascular, and fibrotic tissue

Cardiac injury models have been a long-standing interest, with reported effects on cell survival, vascular response, and scar composition. Fibrosis literature across heart, kidney, liver, and lung frequently invokes Tβ4 or its Ac-SDKP fragment. Findings are model-dependent and have not been translated into approved clinical use.

Musculoskeletal and connective tissue

Muscle, tendon, and ligament repair models are widely discussed in the applied research community and are the subject of several of our companion articles on muscle-tear mechanisms and tendinopathy-related models. The mechanistic rationale is migration of repair-competent cells and vascular ingrowth; controlled human data in these indications is scarce.

Neural, ocular, and craniofacial research

Neurorestorative models have examined Tβ4 in the setting of central nervous system injury, and human brain organoid work has been used to evaluate thymosin beta-4 as a candidate intervention target in Alzheimer disease research. Biomaterial work has also described an injectable Tβ4-modified hyaluronic acid hydrogel carrying exosomes, assessed for stem-cell homing and coupled neuronic, angiogenic, and osteogenic responses in a cranial repair model.

Oncology signaling

Researchers should be aware that Tβ4 appears in cancer biology literature as well, not only regenerative literature. A mechanistic study has examined a Tβ4/SLC7A11 signaling axis in the context of breast cancer evolution. Findings like these are why the compound is best understood as a pleiotropic signaling modulator whose direction of effect depends heavily on the tissue context — and why extrapolation from repair models to whole-organism outcomes is unwarranted.

Hair follicle and integumentary models

Follicular research has examined Tβ4 in relation to hair follicle stem cell migration and differentiation in animal models. This is an active but early area, covered in more detail in our hair-related research articles.

Laboratory Handling: Reconstitution and Storage in General Terms

TB-500 is typically supplied as a lyophilized white powder in a sealed vial. Standard laboratory practice for peptides of this class involves the following general principles — specific volumes, concentrations, and schedules are outside the scope of a hub page and are addressed in our handling-specific articles.

• Lyophilized state is the stable state. Dry peptide stored cold and protected from light and moisture is far more stable than any solution. Repeated exposure of the powder to ambient humidity is a common and avoidable source of degradation.
• Reconstitution solvent choice matters. Bacteriostatic or sterile water is standard for laboratory reconstitution. Solvent should be introduced gently down the vial wall rather than directly onto the peptide cake; vigorous shaking can promote aggregation and foaming.
• Solutions are the fragile form. Once in solution, peptides are subject to hydrolysis, oxidation, and microbial contamination. Refrigerated storage, minimal headspace exposure, and avoidance of repeated freeze-thaw cycles are the usual controls.
• Visual inspection is a first-pass screen, not a purity test. Cloudiness, visible particulates, discoloration, or a collapsed cake warrant investigation. A clear solution, however, does not confirm intact peptide — only analytical testing does.
• Documentation. Recording reconstitution date, solvent, lot number, and storage conditions is what makes an experiment reproducible and a degradation question answerable later.

Regulatory and Research-Use Status

This needs to be stated plainly. TB-500 and thymosin beta-4 are not approved by the FDA as drugs for wound repair, musculoskeletal injury, hair growth, cardiac indications, or any other application discussed in the research literature above. Material sold as TB-500 by research-chemical suppliers is not a pharmaceutical product, is not compounded or dispensed under a prescription, and is not intended for human or veterinary use. It is supplied strictly for in vitro and laboratory research by qualified personnel.

Two additional points researchers frequently need. First, the peptide has drawn regulatory attention in the United States as a substance that has not been established as suitable for compounding, and its status in that space has shifted over time — institutions should verify current guidance rather than rely on secondary summaries. Second, TB-500 is reported to be prohibited in competitive sport by anti-doping authorities under categories covering peptide hormones and growth factors, which is relevant to any lab working with athlete-adjacent samples or sports-science protocols.

How Researchers Evaluate Supplier Quality

Because TB-500 is sold outside pharmaceutical manufacturing controls, product quality varies enormously between sources. The evaluation framework that experienced labs use is straightforward.

1. Batch-specific third-party COA. A certificate tied to the exact lot number on the vial, issued by an independent analytical laboratory, is the baseline. A generic or undated COA reused across batches tells you nothing about the vial in hand.
2. HPLC purity chromatogram. The stated purity percentage is only as meaningful as the chromatogram behind it. Researchers look at the trace itself — peak shape, baseline, and the size and position of impurity peaks — not just the headline number.
3. Mass spectrometry identity confirmation. This is the check that answers the TB-500-versus-full-length-Tβ4 ambiguity. The observed mass should match the expected mass for the stated sequence. Purity without identity confirmation is an incomplete picture.
4. Batch traceability. Lot numbers should be printed on the vial or label and map cleanly to published test documents, with synthesis and testing dates visible.
5. Peptide content versus chromatographic purity. These are different measurements. Lyophilized peptide includes counterions and residual water; net peptide content assays address how much actual peptide is in the vial.
6. Sterility and endotoxin data where the research application requires it, particularly for cell-culture work where endotoxin can confound inflammatory endpoints.

Our companion guides walk through how to read each section of a COA and what the common red flags look like in practice.

Where the Open Questions Are

An honest hub page has to say what is not known. For TB-500 and Tβ4, the unresolved questions are substantial.

• Fragment versus full-length equivalence. How faithfully the synthetic fragment reproduces the full protein's biology across different endpoints has not been systematically resolved.
• Human pharmacokinetics. Distribution, metabolism, and clearance characteristics in humans are not well established in the public literature, and most kinetic reasoning is extrapolated from animal work.
• Concentration-response relationships and context dependence. Model systems suggest that effects can differ by tissue, timing, and injury type. A pro-migratory signal is not universally desirable.
• Oncology safety signal. The presence of Tβ4 in tumor-biology pathway literature is an unresolved consideration that argues for caution in any translational reasoning.
• Delivery format. Much of the most rigorous recent work involves engineered carriers, hydrogels, and exosome systems rather than free peptide, raising the question of how much observed activity depends on presentation and local retention.
• Controlled human trials. Across nearly every application area discussed, adequately powered controlled human evidence is absent. Preclinical promise is not clinical evidence, and the gap between the two is where most of this compound's reputation currently sits.

Research-grade TB-500 (Thymosin Beta-4): Real Peptides supplies TB-500 (Thymosin Beta-4) for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore TB-500 (Thymosin Beta-4) research on Real Peptides

The articles below go deeper on the questions researchers ask most about TB-500 (Thymosin Beta-4).

Research timelines & mechanisms

• How Long TB-500 Stays in System — Clearance Facts
• TB-500 Muscle Tear Mechanism — How It Accelerates Repair
• TB-500 Studied Hair Loss — Research & Growth Mechanisms
• Does TB-500 Help Tennis Elbow? Evidence & Mechanisms

Safety & side effects

• TB-500 Interactions: What Researchers Must Know in 2026
• TB-500 Research Alcohol Considerations — Safety Protocols

Buying & quality

• How to Read TB-500 COA — What Purity Means | Real Peptides
• TB-500 Reddit Reviews Community — Real User Experiences

Reconstitution, storage & handling

• How Long Does a TB-500 Vial Last? A 2026 Breakdown
• TB-500 Refrigeration: Crucial Storage Insights for 2026
• TB-500 Reconstituted Cloudy Still Good? (Stability Guide)
• How Long Is TB-500 Stable Once Reconstituted? (Storage

Research questions

• TB-500 Dogs Horses Veterinary Applications — Research Uses
• Signs TB-500 Gone Bad Degraded — Real Peptides
• Thymosin Beta 4: The Peptide Behind Systemic Repair
• Is TB-500 a Growth Hormone? The Real Answer for Researchers
• Thymosin Beta 4: Unpacking Its Role in Healing & Recovery

Stacks & comparisons

• Difference Between KLOW and TB-500 — Real Peptides
• KLOW vs TB-500: A Deep Dive into Research Peptides in 2026

Legal & regulatory

• Is TB-500 Banned by WADA? The Unflinching Answer for Athletes
• TB-500 Legality in 2026: An Expert’s Unflinching Guide

Ordering TB-500 (Thymosin Beta-4) for research

Real Peptides supplies TB-500 (Thymosin Beta-4) as a research-use-only reference material: lyophilized powder in a sealed vial, labeled with the lot number that matches its published certificate of analysis. Every batch is tested by an independent laboratory before it ships, and the certificate is published before purchase, so a researcher can read the purity result for the exact lot they are ordering.

• Product page: TB-500 (Thymosin Beta-4) for research, with the vial formats currently stocked and the certificate for the batch shipping now.
• Certificates: search any lot number at the certificate lookup; reports stay on file after a batch sells out.
• Shipping: orders dispatch within 24 hours on business days from inventory in Florida and California to every US state; see research peptides by location.
• Related compounds: browse the full research peptide catalog.

Nothing on this page is medical advice or guidance on administering any compound. TB-500 (Thymosin Beta-4) is not for human or animal use, and buyers confirm they are 21 or older and purchasing for laboratory research.

How is TB-500 different from full-length Thymosin Beta-4?

Thymosin Beta-4 is a 43-amino-acid, naturally occurring intracellular polypeptide found in most mammalian cell types and present at high concentration in platelets and wound fluid. The label "TB-500" is used in the research-chemical trade for material based on the actin-binding region of that parent molecule, usually described around the conserved LKKTETQ motif, although some suppliers apply the name to the full-length sequence. Because of this ambiguity, the first question a laboratory buyer should resolve is which molecular entity the certificate of analysis actually describes — the fragment, the acetylated fragment, or the complete peptide — since molecular weight, retention behaviour and comparative data all differ. The functional overlap is the actin interaction itself, outlined in more detail in the discussion of actin sequestration and the longer treatment of the full Thymosin Beta-4 actin mechanism. Published work on the parent protein is considerably deeper than work on short fragments, so extrapolating between them is an assumption rather than an established equivalence. Researchers comparing the two entities alongside other repair-oriented sequences often start with a side-by-side overview of how TB-500 compares with other research peptides before designing any in vitro comparison.

What do preclinical tendon and ligament studies examine with TB-500?

Connective-tissue work with Thymosin Beta-4 and its actin-binding fragment generally uses rodent or rabbit models of tendon transection, collagenase-induced tendinopathy, or ligament injury, with outcome measures such as histological collagen organisation, tenocyte proliferation and migration in culture, cross-sectional area, and mechanical testing of explanted tissue. The mechanistic rationale is that G-actin sequestration influences cytoskeletal remodelling, which in turn affects how tenocytes and fibroblasts migrate into a defect, and that the peptide has been examined for effects on angiogenesis and inflammatory signalling within the healing zone. Published results across these models are heterogeneous, and differences in species, injury model, timing and endpoint selection make direct pooling difficult. A summary of the published landscape in this area is collected under TB-500 and tendon injury research, with the signalling-level discussion kept separately in how TB-500 is studied in tendon injury models. Because tendon healing is partly a fibrosis problem — scar collagen versus organised collagen — many groups read tendon endpoints alongside the markers described in the anti-fibrotic research guide and the broader tissue repair literature. None of this work establishes a defined effect in humans.

How does TB-500 compare with other repair-oriented research peptides?

Laboratories evaluating TB-500 usually place it next to other sequences studied for tissue remodelling, angiogenesis or cytoskeletal signalling, and the useful comparison points are mechanism, depth of published literature, and analytical tractability rather than marketing claims. TB-500 is distinguished by its actin-binding mechanism: rather than acting primarily through a classical membrane receptor, the parent protein buffers monomeric G-actin and influences filament dynamics, with downstream reports on cell migration, angiogenic signalling and inflammatory mediators. Other candidate compounds in this space act through growth-factor pathways, nitric-oxide signalling or collagen-matrix effects, so they generate different endpoint panels and different confounders. Comparative framing is set out in TB-500 versus other research peptides and in the survey of alternatives examined in 2026 literature. A second comparison axis is practical: peptide length, solubility behaviour, lyophilised stability and ease of confirming identity by mass spectrometry all affect how reliably a bench comparison can be run, points covered in the buying guide for researchers. An overview of the reported effects attributed to the peptide in model systems is kept in the benefits discussed in the literature, all of it preclinical.

What cardiac models has Thymosin Beta-4 been studied in?

Cardiac interest in Thymosin Beta-4 grew from developmental biology, where the protein was examined in epicardial cell biology, coronary vessel formation and embryonic heart development. Subsequent preclinical work has used rodent models of myocardial infarction and ischaemia-reperfusion, with endpoints including infarct size by histology, echocardiographic measures of ventricular function, capillary density, and markers of epicardial progenitor activation. Mechanistically, investigators have examined whether actin sequestration and associated cytoskeletal changes influence cardiomyocyte survival signalling, endothelial cell migration and the formation of new vasculature, and whether epicardium-derived cells can be re-activated after injury. Results differ between laboratories, injury models and timing windows, and translation to clinical cardiology remains unestablished. The mechanistic literature is summarised in cardiac mechanisms research and the regeneration-focused material in TB-500 and cardiac regeneration. Readers tracking how these endpoints are read over time in animal work will find the discussion in how cardiac research with TB-500 is structured and the broader overview at TB-500 for cardiac health research. All of this is laboratory and animal work; material sold as TB-500 is for research use only and not for human consumption.

What does the ocular and corneal literature report?

The cornea is a convenient model tissue for epithelial repair studies because injury can be standardised, the healing surface is directly observable, and re-epithelialisation rate is measurable without sacrificing the animal. Thymosin Beta-4 has been examined in corneal epithelial wound models for effects on epithelial cell migration, inflammatory cell infiltration, apoptosis markers and stromal remodelling, and the molecule has also appeared in investigational ophthalmic formulation research. The mechanistic hypothesis is consistent with the rest of the field: by influencing actin dynamics, the peptide may alter how epithelial sheets migrate across a defect, with secondary effects on inflammation and matrix deposition. Summaries of the published mechanistic work are collected in corneal healing mechanisms and research timelines and in the general overview of TB-500 and corneal repair. Laboratories comparing ocular endpoints with skin or tendon models often read these alongside TB-500 for corneal healing research and the methodological notes in how corneal healing research is designed. Corneal data should not be generalised to other tissues, since epithelial turnover kinetics and the avascular stromal environment differ substantially from vascularised connective tissue.

Why does TB-500 appear in hair follicle research?

Hair follicles cycle through growth, regression and rest phases, and that cycling depends on stem-cell populations in the bulge region, on cell migration and on local vascular and matrix signalling — all processes in which actin dynamics have a plausible role. Thymosin Beta-4 has been examined in rodent hair-cycle studies and in follicle-derived cell culture for effects on stem-cell migration, differentiation markers and the transition from telogen to anagen, as well as for interactions with extracellular matrix-degrading enzymes that allow cells to move through the follicular environment. The literature in this area is smaller than the wound-healing literature and consists largely of animal and in vitro work, so claims about scalp outcomes in people are not supported by it. The cell-biology background is set out in TB-500 and hair follicle stem cells, with the published study landscape reviewed in hair growth clinical evidence and a general orientation in TB-500 for hair growth research. For any laboratory running follicle work, endpoint definition matters more than the compound: follicle counts, cycle staging and histological scoring are not interchangeable measures.

What is known about TB-500 half-life, clearance and solution stability?

Two different stability questions get confused. The first is biological persistence — how long the peptide and its fragments remain measurable in a model organism before proteolytic clearance and renal elimination. Small, unstructured peptides generally clear quickly, and the parent protein's intracellular abundance complicates interpretation of circulating measurements, so pharmacokinetic figures reported for Thymosin Beta-4 vary by species and assay method. The published background on this is gathered in TB-500 half-life research and in the discussion of bioavailability and absorption factors. The second question is chemical: how the material behaves in the vial. Lyophilised peptide stored cold, dark and dry is generally the most stable form, while material in solution is subject to hydrolysis, oxidation of susceptible residues, aggregation and microbial contamination over time, with temperature and repeated freeze-thaw cycles as the main accelerants. Laboratories that need defensible data usually re-run analytical checks rather than assume shelf stability; the degradation pathways relevant to solution-state material are outlined in TB-500 degradation after reconstitution. Analytical detection approaches used to track the peptide and its metabolites are summarised in biomarkers and detection methods.

How do laboratories confirm TB-500 identity and purity by HPLC and mass spectrometry?

Two orthogonal analyses do most of the work. Reversed-phase HPLC separates the target peptide from truncated sequences, deletion products and synthesis-related impurities, and the resulting chromatogram gives a percentage purity figure based on peak area at a stated wavelength — typically 214 nm for the peptide bond. Mass spectrometry, usually ESI or MALDI, confirms that the main peak has the expected molecular mass, which HPLC alone cannot establish; a clean single peak of the wrong compound still looks clean. A usable certificate of analysis therefore shows both traces, names the lot, states the method conditions and carries a date, rather than presenting a bare numeric claim. Supporting data may include water content, net peptide content, counter-ion information and sterility or endotoxin testing depending on the intended laboratory use. Independent third-party testing is the strongest form of verification because it removes the supplier from the analytical chain. Practical criteria for reading these documents are set out in how to tell if a peptide supplier is legitimate and in the researcher buying guide, with sourcing considerations covered at TB-500 for sale and detection methodology in biomarkers and detection methods.

What anti-fibrotic signalling does TB-500 research examine?

Fibrosis research asks whether a molecule shifts tissue repair away from disorganised scar collagen and toward organised matrix. In models using Thymosin Beta-4 and its actin-binding fragment, the readouts are familiar to anyone working in this field: collagen I and III deposition, alpha-smooth-muscle-actin as a myofibroblast marker, TGF-beta pathway components, matrix metalloproteinases and their tissue inhibitors, and histological fibrosis scoring in cardiac, hepatic, renal, dermal or pulmonary tissue. The proposed mechanistic link is that altering actin monomer availability affects myofibroblast differentiation and the mechanotransduction signalling that sustains it, with additional reported effects on inflammatory cell recruitment during the early repair window. Published findings are mixed and model-dependent, and anti-fibrotic activity in one organ does not predict the same behaviour in another. The mechanism-level material is collected in how anti-fibrotic research with TB-500 is framed and the broader review in the anti-fibrotic complete guide. Transcriptional endpoints used in this work are discussed in gene expression mechanisms and research applications, while the wider signalling picture appears in downstream effects and mechanisms. This remains preclinical research with no established clinical application.

References

Peer-reviewed sources on TB-500 (Thymosin Beta-4) indexed in PubMed, listed for research context. Real Peptides supplies TB-500 (Thymosin Beta-4) for laboratory research use only.

1. Thymosin β4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway. Clinical science (London, England : 1979), 2026. PMID 42417058. doi:10.1042/CS20261084
2. Sprayable bioadhesive microcarriers loaded with Tβ4-Engineered ADSC exosomes for diabetic wound healing. Bioactive materials, 2026. PMID 42383202. doi:10.1016/j.bioactmat.2026.06.024
3. Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. Stem cell reports, 2025. PMID 40816274. doi:10.1016/j.stemcr.2025.102601
4. Mechanistic study of the Tβ4/SLC7A11 signaling pathway regulating breast cancer evolution. Cellular signalling, 2025. PMID 40912522. doi:10.1016/j.cellsig.2025.112111
5. Thymosin β4 Regulates Tissue Inflammatory Response in Mouse Nonalcoholic Fatty Liver Disease by Promoting Macrophage M2-Type Polarization. Journal of inflammation research, 2025. PMID 40322536. doi:10.2147/JIR.S492814
6. Injectable Thymosin β4-Modified Hyaluronic Acid Hydrogel with Exosomes for Stem Cell Homing and Neuronic-Angiogenic-Osteogenic Coupled Cranial Repair. ACS nano, 2025. PMID 40528381. doi:10.1021/acsnano.4c10386
7. Secreted Expression of Thymosin β4 from Pinctada fucata in Pichia pastoris and Its Biological Activity. Biology, 2025. PMID 40427742. doi:10.3390/biology14050553
8. Thymosin β4 and the anti-fibrotic switch. International immunopharmacology, 2023. PMID 36580759. doi:10.1016/j.intimp.2022.109628